Literature DB >> 32329865

Comparison of IMRT and VMAT radiotherapy planning for Graves' ophthalmopathy based on dosimetric parameters analysis.

S-C Wang1, J Wu, X-Q Xie, X-L Liu, Y Luo, F Wang, Z-P Li, B-L Qu, J-B Kang, D-B Wu, W-M Li, R-Y Wang.   

Abstract

OBJECTIVE: To compare volumetric modulated arc therapy (VMAT) and intensity-modulated radiation therapy (IMRT) for the treatment of Graves' ophthalmopathy (GO) based on the dosimetric data. PATIENTS AND METHODS: 19 patients diagnosed with GO were recruited in this study. For each patient, a dual-partial-arc VMAT plans and a 7-fixed-field IMRT plans were replanned. Dosimetric parameters of the targets and organs at risk (OARs) originated from the two kinds of plans were compared and analyzed.
RESULTS: Homogeneity index (HI) was superior in IMRT plans compared with VMAT (p=0.0014) but there was no significant statistical difference in conformity index (CI) between them (p=0.0673). IMRT plans revealed advantage in the OARs protection especially for the left and right lenses, optic nerves and eyeballs (p<0.05).
CONCLUSIONS: VMAT and IMRT are both feasible techniques in radiotherapy in GO from the perspective of dosimetric parameters. Homogeneity and OAR protection were slightly superior in IMRT plans compared with VMAT plans.

Entities:  

Year:  2020        PMID: 32329865     DOI: 10.26355/eurrev_202004_20856

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

1.  Analysis of EPID Transmission Fluence Maps Using Machine Learning Models and CNN for Identifying Position Errors in the Treatment of GO Patients.

Authors:  Guyu Dai; Xiangbin Zhang; Wenjie Liu; Zhibin Li; Guangyu Wang; Yaxin Liu; Qing Xiao; Lian Duan; Jing Li; Xinyu Song; Guangjun Li; Sen Bai
Journal:  Front Oncol       Date:  2021-09-14       Impact factor: 6.244

2.  Treatment of benign tumours and related pathologies with radiotherapy: experience of the General Hospital of Mexico.

Authors:  Yicel Bautista Hernandez; Karina Vazquez Gomez; Ana Laura Lopez
Journal:  Rep Pract Oncol Radiother       Date:  2022-09-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.